Search
Talking siRNAs with the CEO of Silence Therapeutics
- blonca9
- Feb 26, 2024
- 1 min read
Craig Tooman describes Silence's two lead programs targeting Lp(a) and polycythemia vera, as well as how the company is trying to execute on a broader platform.